5/14
12:10 am
mack
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/10
04:30 pm
mack
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Low
Report
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
5/9
07:30 am
mack
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Low
Report
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
4/30
05:15 pm
mack
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Low
Report
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
3/27
04:50 pm
mack
Merrimack Receives $225 Million Milestone Payment from Ipsen [Yahoo! Finance]
Low
Report
Merrimack Receives $225 Million Milestone Payment from Ipsen [Yahoo! Finance]
3/27
04:30 pm
mack
Merrimack Receives $225 Million Milestone Payment from Ipsen
Low
Report
Merrimack Receives $225 Million Milestone Payment from Ipsen
3/7
04:30 pm
mack
Merrimack Reports Full Year 2023 Financial Results
Low
Report
Merrimack Reports Full Year 2023 Financial Results
3/4
07:17 am
mack
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company [Yahoo! Finance]
Low
Report
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company [Yahoo! Finance]